A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

carcinoma, non-small cell lung, artemide-lung04, rilvegostomig (azd2936), non-small cell lung cancer (nsclc), bi-specific antibody, t-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (tigit), egfr, alk and ros1 testing, programmed cell death protein (pd-l1), pembrolizumab, interventional, phase3